Bristol Myers Squibb ended its collaboration with Cellares, a cell-therapy CDMO, citing manufacturing requirements tied to Breyanzi (lisocabtagene maraleucel). The termination follows reports that Cellares’ Cell Shuttle system could not meet the necessary commercial needs. Cellares disputed BMS’s characterization, saying the Cell Shuttle has already manufactured GMP drug product for FDA-regulated clinical programs with doses meeting release specifications and on-time delivery. The dispute now raises practical execution questions for CAR-T manufacturing pathways and creates financial pressure that the CDMO said could require restructuring and operational resizing.